Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03904758
Other study ID # FNO-ENT-Pepsin
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 1, 2019
Est. completion date December 31, 2021

Study information

Verified date December 2022
Source University Hospital Ostrava
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The diagnostics of extraesophageal reflux (EER) is challenging. Currently, 24-h dual-probe esophageal pH monitoring or impedance is considered the best diagnostic method for EER. The 24-h oropharyngeal pH monitoring is a newer method aimed at detecting episodes of reflux to the oropharynx. Unfortunately, all these methods have many disadvantages. Pepsin detection in saliva would be an almost ideal diagnostic technique. However, data of its reliability is lacking. The aim of the study is to compare results of oropharyngeal pH monitoring and esophageal impedance monitoring, compared to a quantified pepsin presence in the saliva obtained immediately prior to 24-hour monitoring and to evaluate the feasibility of this technique as a routine option of diagnosing the presence of extraesophageal reflux.


Description:

Extraesophageal reflux (EER) has recently been found to be a risk factor for many head and neck pathologies. Many studies have shown that contact between the refluxed content and mucous tissue can cause local inflammation and edema and thus facilitate the development of inflammation. Although important, the diagnostics of EER is not easy. The simplest means of collecting information about reflux problems is questioning potential sufferers. However, although many questionnaires have been developed over the last few years, questioning is still not a suitable technique for the evaluation of EER, the reason being that symptoms of EER are heterogeneous and very common. Currently, 24-h dual-probe esophageal pH monitoring or impedance is considered the best diagnostic method for EER. The 24-h oropharyngeal pH monitoring is a newer method aimed at detecting episodes of reflux to the oropharynx and seems to generate similar results. However, these methods may not be tolerated well. Moreover, the position of the sensor, which is placed in the hypopharynx or oropharynx, does not precisely reflect the amount of reflux content that reaches larynx, nasopharynx, nasal cavity or middle ear. Another disadvantage of pH monitoring is that it enables only a short-term analysis over a timespan of just 24-48 h. Detection of pepsin in fluids and tissues is considered by some authors to be perhaps more appropriate than pH monitoring because it reflects the long-term effects of EER and proves that EER is truly affecting the examined region. This is particularly true for more distant regions like the middle ear. Pepsin detection in saliva would be very well tolerated and fast diagnostic method. However, data of its reliability are lacking. The aim of the study is to compare results of oropharyngeal pH monitoring and esophageal impedance monitoring, compared to a quantified pepsin presence in the saliva obtained immediately prior to 24-hour monitoring and to evaluate the feasibility of this diagnostic option as a routine method.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date December 31, 2021
Est. primary completion date November 30, 2021
Accepts healthy volunteers No
Gender All
Age group 15 Years to 99 Years
Eligibility Inclusion Criteria: - suspicion of EER indicated for diagnostics Exclusion Criteria: - head and neck cancer - not-signing of the informed consent with participation in the study - intolerance of 24-hour monitoring - treatment with proton pump inhibitors

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Pepsin in saliva test
The presence of pepsin in the saliva will be tested in both groups of patients.

Locations

Country Name City State
Czechia University Hospital Ostrava Ostrava Moravian-Silesian Region

Sponsors (1)

Lead Sponsor Collaborator
University Hospital Ostrava

Country where clinical trial is conducted

Czechia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Reflux symptom index (RSI) Reflux symptom index is a standard tool in the form of a questionnaire scale where the patients evaluate their problems related to reflux on a scale of 0 (no problems) to 5 (severe). The value of RSI over 13 may be indicative of serious reflux-related problems. 24 hours
Primary Reflux finding score (RFS) Reflux finding score is a standard tool for assessing the presence and severity of reflex, evaluating reflux symptoms in eight areas. 24 hours
Secondary Presence of pepsin in the saliva The presence of pepsin in the saliva will be assessed. 24 hours
See also
  Status Clinical Trial Phase
Completed NCT04581174 - Effect of Extraesophageal Reflux on Inferior Nasal Turbinates Hypertrophy N/A
Recruiting NCT04984304 - Individualized Diagnosis and Treatment of Extraesophageal Reflux in Patients With Chronic Cough N/A
Completed NCT01755221 - Positive Predictive Value of the Dx-pH Probe for Predicting PPI Response in LPR